Lenard M Silverman, MD | |
3550 Preston Ridge Road, Internal Medicine Health Care Team A, Alpharetta, GA 30005 | |
(770) 663-3122 | |
(770) 663-3149 |
Full Name | Lenard M Silverman |
---|---|
Gender | Male |
Speciality | Internal Medicine |
Location | 3550 Preston Ridge Road, Alpharetta, Georgia |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1467465963 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | 038094 (Georgia) | Primary |
Entity Name | The Southeast Permanente Medical Group |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1245266956 PECOS PAC ID: 6204829013 Enrollment ID: O20040407000370 |
News Archive
Growing evidence suggests that SARS-CoV-2, the novel coronavirus that causes COVID-19, can be spread by asymptomatic people via aerosols - a reality that deeply underscores the ongoing importance of regular widespread testing, wearing masks and physical distancing to reduce the spread of the virus, say Kimberly Prather and colleagues in a new Perspective.
A new study appearing in the July issue of Psychological Science, a journal of the Association for Psychological Science, reports that watching an actor smoke on the big screen may make smokers more likely to continue smoking in the future, and make nonsmokers more favorably disposed toward smoking.
Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.
BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D, the company's controlled-release latanoprost insert for the treatment of glaucoma.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Lenard M Silverman, MD 3495 Piedmont Road Ne, Nine Piedmont Center, Atlanta, GA 30305-1736 Ph: (404) 364-7000 | Lenard M Silverman, MD 3550 Preston Ridge Road, Internal Medicine Health Care Team A, Alpharetta, GA 30005 Ph: (770) 663-3122 |
News Archive
Growing evidence suggests that SARS-CoV-2, the novel coronavirus that causes COVID-19, can be spread by asymptomatic people via aerosols - a reality that deeply underscores the ongoing importance of regular widespread testing, wearing masks and physical distancing to reduce the spread of the virus, say Kimberly Prather and colleagues in a new Perspective.
A new study appearing in the July issue of Psychological Science, a journal of the Association for Psychological Science, reports that watching an actor smoke on the big screen may make smokers more likely to continue smoking in the future, and make nonsmokers more favorably disposed toward smoking.
Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.
BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D, the company's controlled-release latanoprost insert for the treatment of glaucoma.
› Verified 8 days ago
Jeffrey Obiora, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3180 N Point Pkwy Ste 303, Alpharetta, GA 30005 Phone: 678-205-9004 | |
Dr. Jay Arthur Cherner, M.D. Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 3330 Preston Ridge Rd, Suite 220, Alpharetta, GA 30005 Phone: 770-410-1600 Fax: 770-410-0006 | |
Randy Turkel, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 11600 Atlantis Place, Suite B, Alpharetta, GA 30022 Phone: 770-664-4449 Fax: 770-777-6496 | |
Xiaowen Wu, MD Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 10800 Jones Bridge Rd, Ste A, Alpharetta, GA 30022 Phone: 678-867-0135 Fax: 678-867-0137 | |
Dr. Justin Chen, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 2575 Northwinds Pkwy, Alpharetta, GA 30009 Phone: 800-930-0748 | |
Irfan Ali Syed, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3584 Old Milton Pkwy, Alpharetta, GA 30005 Phone: 678-691-3388 Fax: 678-395-7702 | |
Arezou Fatemi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3180 N Point Pkwy, Ste 303, Alpharetta, GA 30005 Phone: 678-205-9004 Fax: 678-205-9005 |